Approval was largely expected as, earlier this year, the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (:EMA) had issued a positive opinion regarding Inlyta. The EU ...

Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...

Pfizer (NYSE: PFE) had big expectations for Inlyta when it launched in 2012. Over the past few years, though, it's fallen out of favor as new, more effective treatments set up camp in its neighborhood ...

Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA® (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today that a ...

Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit ...

Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab. Inlyta (axitinib) alone demonstrated better progression-free survival in patients with ...

Pfizer has been looking to expand kidney cancer drug Inlyta's use to renal cell carcinoma (RCC) patients at a high risk of disease recurrence following surgery—but on that front, it's fallen short.

The National Institute for Health and Care Excellence has published final draft guidelines endorsing the use of Pfizer’s Inlyta (axitinib) by the National Health Service to treat advanced kidney ...

Pfizer’s hopes of reversing the decline of its renal cell carcinoma (RCC) treatment Inlyta have taken a knock with a failed phase III trial in patients with less advanced disease. The ATLAS study was ...

Pfizer PFE and its German partner Merck KGaA announced that the FDA has approved their supplemental Biologics License Application (sBLA) for PD-L1 inhibitor, Bavencio (avelumab). The sBLA was looking ...

When Bristol Myers Squibb and Exelixis first unveiled kidney cancer data for the combination of Opdivo and Cabometyx last fall, industry watchers couldn’t determine a clear winner between that duo and ...